阿托伐他汀序贯治疗对接受急症PCI术急性心肌梗死患者缺血修饰白蛋白的影响

发布时间：2018-05-07 02:06

本文选题：序贯治疗 + 经皮冠状动脉介入治疗　；参考：《介入放射学杂志》2016年09期

【摘要】：目的探讨阿托伐他汀序贯治疗对接受急症经皮冠状动脉介入治疗(PCI)急性心肌梗死患者血清缺血修饰白蛋白(IMA)的影响。方法收集2010年9月至2014年1月收治的符合纳入标准的83例急性ST段抬高型心肌梗死(STEMI)患者,随机分为阿托伐他汀常规治疗组(n=40,对照组)和序贯治疗组(n=43),对照组阿托伐他汀20 mg/d,序贯治疗组术前80 mg/d,术后40 mg/d,3个月后20 mg/d。观察术前及术后2、4、6、8、10、12、14 h IMA,术中及术后6个月主要心血管不良事件(MACE)。结果序贯治疗组PCI术后血清IMA水平明显低于常规治疗组,差异有统计学意义(P0.05);序贯治疗组术后6个月MACE发生率明显明显低于常规治疗组,差异有统计学意义(P0.05)。结论阿托伐他汀序贯治疗可显著改善急症PCI患者心肌缺血,对心肌起主要保护作用,并降低术后MACE发生率,安全有效。
[Abstract]:Objective to investigate the effect of Atto vastatin sequential therapy on serum ischemia modified albumin (IMA) in patients with acute myocardial infarction (AMI) undergoing percutaneous coronary intervention (PCI). Methods from September 2010 to January 2014, 83 patients with acute ST-segment elevation myocardial infarction (STEMI) who met the inclusion criteria were collected. They were randomly divided into Atto vastatin routine treatment group (control group) and sequential treatment group (Atto vastatin 20 mg / d, sequential treatment group, preoperative 80 mg / d, postoperative 40 mg / d, 3 months later, 20 mg / d). Before and after operation, the IMA was observed at 2: 4, 8, 10, 12 and 14 h. The major adverse cardiovascular events were observed during and 6 months after operation. Results the serum IMA level in sequential treatment group was significantly lower than that in routine treatment group (P 0.05), and the incidence of MACE in sequential treatment group was significantly lower than that in routine treatment group 6 months after operation (P 0.05). Conclusion Atto vastatin sequential therapy can significantly improve myocardial ischemia in patients with acute PCI, play a major role in myocardial protection, and reduce the incidence of MACE after operation, which is safe and effective.
【作者单位】：核工业四一六医院心内科;
【分类号】：R542.22

【相似文献】